Effect of TYB-2285 on passive cutaneous anaphylaxis in rats.
1. TYB-2285 (1-30 mg/kg p.o.) inhibited ovalbumin (OA)- and dinitrophenyl-Ascaris (DNPAs)-induced passive cutaneous anaphylaxis (PCA) in a dose-dependent manner. 2. The ED50 of TYB-2285 and ketotifen fumarate on OA-induced PCA were 0.5 and 3.9 mg/kg, respectively. The ED50 of TYP-2285 and amlexanox on DNP-As-induced PCA were 3.5 and 0.9 mg/ kg, respectively. 3. TYB-2285 (3-30 mg/kg p.o.) inhibited histamine consumption at the PCA site. 4. Unlike cyproheptadine or amlexanox, TYB-2285 (30 mg/kg p.o.) did not inhibit histamine-, serotonin-, ascites-, 48/80-, or A23187-induced capillary permeability. It inhibited dextran-induced capillary permeability slightly. 5. These results demonstrate that TYB-2285 inhibits PCA by inhibiting histamine release, although it does not inhibit capillary permeability.
Watanabe
A
A
Department of Pharmacology, Toyobo Co. Ltd., Shiga, Japan.
Tominaga
T
T
Shutoh
H
H
Hayashi
H
H
Tsuji
J
J
Koda
A
A
Nagai
H
H
Kumazawa
Y
Y
Shimada
H
H
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D000947:Antigens, Helminth / Q000276:immunology; D017165:Ascaris suum / Q000276:immunology; D002199:Capillary Permeability / Q000187:drug effects; D004136:Dinitrobenzenes / Q000276:immunology; D004305:Dose-Response Relationship, Drug; D006632:Histamine / Q000378:metabolism; D008297:Male; D009570:Nitriles / Q000494:pharmacology*; D010047:Ovalbumin / Q000276:immunology; D010323:Passive Cutaneous Anaphylaxis / Q000187:drug effects* / Q000276:immunology; D051381:Rats; D013997:Time Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000947:Antigens, Helminth; D004136:Dinitrobenzenes; D009570:Nitriles; C081050:3,5-bis(acetoxyacetylamino)-4-chlorobenzonitrile; D006632:Histamine; D010047:Ovalbumin